SLC5A2 and Alzheimer disease: Furthermore, our finding that 1 mg/kg/day of Enavogliflozin mitigated cognitive decline in 5XFAD mice is particularly promising when compared to studies using higher doses (10 mg/kg/day) of other SGLT2 inhibitors such as Empagliflozin or Canagliflozin in AD models (Hierro‐Bujalance et al. 2020; Khamies et al. 2024).